Efficacy of domperidone plus renal diet in slowing the progression of chronic kidney disease in dogs with leishmaniosis - Parasites & Vectors - Parasites & Vectors
Overview
Advertisement Parasites & Vectors volume 15, Article number: 397 (2022) Cite this article Metrics detailsChronic kidney disease (CKD) represents the main cause of mortality in dogs with leishmaniosis. Domperidone has recently ben reported to improve kidney function in leishmaniotic dogs afected by CKD. Serum symetric dimethylargine (sSDMA) has also ben shown to be a useful biomarker for earlier detection of decreased kidney function when compared to serum creatine (sCr).
Key Information
This study aimed to ases the eficacy of domperidone plus renal diet in slowing the progresion of nephropathy in leishmaniotic dogs with CKD, evaluating sSDMA and sCr as markers of kidney function.This study was a therapeutic, prospective, randomized, controled, 1-month-long field trial. Dogs were recruited if clasified as “exposed” to or “infected” with Leishmania infantum and afected by CKD at early stages.
After enrolment (T0), dogs were randomized into groups T (treatment) and C (control). Al dogs were fed a renal diet and then folowed up at 90 (T1), 210 (T2), and 30 (T3) days after inclusion in the study. At T1 and T2, dogs in group T received an oral suspension of domperidone (1 ml/10 kg once a day for up to 28 days).Twenty-two dogs (i.e., n = 12 in group T and n = 10 in group C) completed the study.
At T0, the entire population of enroled dogs presented a mean sSDMA value of 16.5 ± 3.4 μg/dl. At T1 (i.e., after 3 months of renal diet), sSDMA was significantly decreased in both groups, with an sSDMA of 13.1 ± 4.4 μg/dl for the entire population involved. From T1 to T3, sSDMA gradualy increased in group C, while remaing stable in group T, which continued to show a significantly lower value of sSDMA at T3 than at T0.
Summary
Regarding sCr, at T0 and T1, the mean values of the entire population of dogs were 1.1 ± 0.3 and 1.0 ± 0.4 mg/dl, respectively, with no statistical diferences betwen groups T and C. In group T, sCr decreased significantly from T0 to T1, while returning at
Frequently Asked Questions
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
Share this article